Join Meeting Now

Your data is secure and never shared.

Brazil
August 2026

Brazil Medical Device Market Size, Share & Forecast, By Product Type, Care Setting & Technology, 2026-2031

2031

The Brazil Medical Device Market worth USD 16,478 million in 2025 is growing at a CAGR of 6.15% to reach USD 23,573 million by 2031. Philips, GE HealthCare, Siemens Healthineers, Abbott and Medtronic are the major companies operating in this market.

Report Details

Base Year

2025

Pages

94

Region

Brazil

Author

Ken Research

Product Code
KR944-2026

CHAPTER 1 - MARKET SUMMARY

Market Overview

The Brazil Medical Device Market serves a mixed public-private healthcare system in which equipment, diagnostics, implants and consumables are purchased through institutional contracts, distributors and public procurement. Demand is reinforced by procedure intensity: SUS recorded 14.4 million hospitalizations in 2025, with surgical admissions continuing to expand. Higher procedure throughput directly raises recurring consumption of diagnostics, implants and single-use devices.

Demand is concentrated in the Southeast, led by São Paulo, Rio de Janeiro and Minas Gerais, where advanced hospitals, laboratories, distributors and manufacturers form Brazil's deepest medical technology cluster. Demographics reinforce this position: people aged 65 and above represented approximately 12.2% of the Southeast population in the 2022 Census, above the national average, supporting higher diagnostic and chronic-care utilization.

Market Value

USD 16,478 million

2025

Dominant Region

Southeast

2025

Dominant Segment

Product Type

fastest growing: Technology

Total Number of Players

1,618+

2025

Future Outlook

The Brazil Medical Device Market is projected to increase from USD 16,478 million in 2025 to USD 23,573 million by 2031, representing a modeled forecast CAGR of 6.15%. This follows an estimated historical CAGR of 10.95% during 2020-2025, when post-pandemic diagnostic normalization, hospital procedure recovery, imported technology demand and healthcare capacity expansion lifted market value. The forecast assumes moderation from the stronger historical cycle while maintaining structural demand from aging, chronic disease management, hospital modernization, surgical procedures and private healthcare coverage. The latest 2026 operating checkpoint, with first-quarter apparent consumption growth of 4.8%, remains consistent with a normalized medium-term expansion path.

Growth through 2031 is expected to become increasingly mix-driven. Higher-value imaging, diagnostics, connected monitoring, minimally invasive devices and software-enabled technologies should outpace conventional equipment, while consumables retain recurring revenue characteristics. The modeled device-volume index rises from 100 in 2025 to 127.7 in 2031, implying approximately 4.16% annualized volume growth, while the modeled ASP index rises from 100 to 112. Localization incentives could gradually redirect selected procurement toward domestic production, although technologically complex categories should remain import-dependent. Regulatory digitization, UDI implementation and greater reliance on international regulatory assessments can improve launch predictability for compliant manufacturers.

6.15%

Forecast CAGR

USD 23,573 Mn

2030 Projection

Base Year

2025

Historical Period

2020-2025

Forecast Period

2026-2031

Historical CAGR

10.95%

CHAPTER 2 - SCOPE OF REPORT

Scope of the Market

Click to Explore Interactive Mind Map

CHAPTER 3 - Key Stakeholders

Key Target Audience

Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning.

Investors

CAGR, import exposure, margin pools, capex intensity, regulation

Corporates

tender access, localization, distributor margins, approvals, service coverage

Government

self-sufficiency, SUS procurement, compliance, innovation, supply resilience

Operators

uptime, installed base, consumables, interoperability, maintenance, training

Financial institutions

equipment finance, working capital, currency risk, covenants, demand

What You'll Gain

  • Market sizing and trajectory
  • Regulatory and procurement mapping
  • Import exposure indicators
  • Segment structure and levers
  • Competitive landscape shortlist
  • CEO-grade risk priorities

80+

Pages of insights

CHAPTER 4 - Market Size & Growth

Market Size, Growth Forecast and Trends

This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers.

Historical & Projected Market Size ($ Million)

Year-over-Year Growth Rate (%)

Market Value vs Volume Growth (%)

Historical Market Performance (2020-2025)

Historical performance was characterized by strong normalization and healthcare-capacity expansion. The modeled growth peak occurred in 2023 at 14.15%, followed by 11.50% in 2024 and moderation to 7.00% in 2025. The 2025 outcome aligns with reported apparent-consumption growth of 7%, while domestic manufacturing expanded only 2.6%. The divergence indicates that imported systems, diagnostics and higher-value technologies captured a disproportionate share of incremental demand. Procedure recovery, hospital expansion and private-sector equipment replacement also strengthened the market, while the progressively lower 2025 growth rate marked transition from catch-up demand toward a more normalized investment cycle.

Forecast Market Outlook (2026-2031)

The forecast assumes a steadier expansion profile with annual value growth near 6.0%-6.3%, producing a 6.15% CAGR through 2031. The normalized device-volume index is projected to expand at approximately 4.16% annually, while the modeled ASP index rises approximately 1.91% annually, reflecting greater penetration of high-value diagnostics, connected systems and minimally invasive technologies. First-quarter 2026 apparent consumption growth of 4.8% provides a conservative near-term operating signal. Upside would emerge from stronger domestic production incentives, faster technology replacement and diagnostic investment, while slower public procurement or import-cost inflation would restrain unit growth.

CHAPTER 5 - Market Data

Market Breakdown

The Brazil Medical Device Market is transitioning from post-pandemic normalization toward a steadier investment cycle, with value growth increasingly influenced by technology mix, imported equipment economics and recurring diagnostic and consumables demand.

Market Breakdown

Historical Data (2020-2024) • Base Data (2025) • Forecast Data (2026-2031)

Year
Market Size (USD Mn)
YoY Growth (%)
Device Volume Index (2025=100)
ASP Index (2025=100)
Medical Device Imports (USD Bn)
Period
2020$9,800 Mn+-66.190
$#%
Forecast
2021$10,900 Mn+11.22%71.992
$#%
Forecast
2022$12,100 Mn+11.01%78.194
$#%
Forecast
2023$13,812 Mn+14.15%87.396
$#%
Forecast
2024$15,400 Mn+11.50%95.498
$#%
Forecast
2025$16,478 Mn+7.00%100.0100
$#%
Forecast
2026$17,467 Mn+6.00%103.9102
$#%
Forecast
2027$18,532 Mn+6.10%108.1104
$#%
Forecast
2028$19,681 Mn+6.20%112.7106
$#%
Forecast
2029$20,921 Mn+6.30%117.6108
$#%
Forecast
2030$22,218 Mn+6.20%122.6110
$#%
Forecast
2031$23,573 Mn+6.10%127.7112
$#%
Forecast

Device Volume Index

100.0 (2025, Brazil). The normalized index separates underlying device throughput from price and technology-mix effects. SUS surgical admissions reached approximately 6.48 million in 2025, expanding procedure-linked demand for implants, diagnostics, instruments and consumables.

ASP Index

100 (2025, Brazil). The index captures changes in mix rather than a single physical device price. Imports reached approximately USD 10.2 billion in 2025 and grew 10.9%, indicating continued exposure to higher-value foreign technology and foreign-exchange-sensitive acquisition costs.

Medical Device Imports

USD 10.2 billion (2025, Brazil). Import value exceeded exports of roughly USD 1.0 billion by a wide margin, making sourcing, regulatory approvals, currency management and localization central strategic variables for manufacturers and distributors.

CHAPTER 6 - Segmentation

Market Segmentation Framework

Comprehensive analysis across key dimensions providing insights into market structure, consumer preferences, and distribution patterns.

No of Segments

7

Dominant Segment

Product Type

Fastest Growing Segment

Technology

Product Type

Medical Equipment
$%
In Vitro Diagnostic Devices
$%
Medical Consumables
$%
Orthopedic and Implantable Devices
$%

Care Setting

Public Hospitals and SUS Facilities
$%
Private Hospitals
$%
Ambulatory and Day Surgery Centers
$%
Diagnostic Laboratories and Clinics
$%

End User

Surgeons and Interventional Specialists
$%
Diagnostic Professionals
$%
Nursing and Critical Care Teams
$%
Patients and Caregivers
$%

Disease Area

Cardiovascular and Metabolic Disorders
$%
Oncology
$%
Orthopedic and Musculoskeletal Disorders
$%
Infectious Disease and General Diagnostics
$%

Channel

Direct Institutional Sales
$%
Authorized Distributors
$%
Public Tenders and Procurement Platforms
$%
E-Commerce and Specialized Retail
$%

Technology

Conventional Electromechanical Devices
$%
Connected and IoMT Devices
$%
Software as a Medical Device
$%
AI-Enabled Diagnostic and Monitoring Devices
$%

Geography

Southeast
$%
South
$%
Northeast
$%
North and Central-West
$%

Key Segmentation Takeaways

Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, consumer preferences, and distribution patterns.

Product Type

Product architecture is the primary revenue-allocation lens because procurement economics differ substantially between capital equipment, diagnostics, recurring consumables and implantable devices. Medical equipment generates high-ticket procurement and service revenue, while in vitro diagnostics provide recurring reagent economics. Hospitals increasingly evaluate total lifecycle cost, uptime, consumable attachment and interoperability rather than acquisition price alone.

Technology

Technology is expected to expand fastest as connected monitoring, software-based medical functionality and AI-assisted diagnostics move from pilots toward routine clinical workflows. The strongest Level-2 momentum is expected in AI-Enabled Diagnostic and Monitoring Devices, supported by digital-health investment, hospital data integration and expanding regulatory frameworks for software-based medical products. Legacy equipment vendors therefore face growing software, cybersecurity and interoperability requirements.

CHAPTER 7 - Regional Analysis

Regional Analysis

Brazil holds the leading medical-device position among major Latin American peer markets, supported by the region's largest domestic demand pool, an extensive public healthcare network and a deeper local manufacturing base. Mexico remains the nearest scale comparator, while Colombia, Chile and Argentina are smaller and generally more import dependent.

Focus Country Ranking

1st

Focus Country Market Size

USD 16,478 Mn

Brazil CAGR (2026-2031)

6.15%

Regional Analysis (Current Year)

Regional Analysis Comparison

MetricBrazilMexicoColombiaChileArgentina
Market Size (USD Mn, 2025)16,4787,8001,5801,4991,015
CAGR (%)6.15%7.50%5.80%7.10%6.14%
Healthcare Expenditure (% of GDP, public benchmark)9.7%5.5%6.0%7.8%9.5%
Import Reliance (Approx. %)43.5%80%82%89%80%

Market Position

Brazil ranks 1st among the selected peers and is identified as Latin America's largest medical-technology market, ahead of Mexico, Colombia and Argentina, supported by scale and a broad healthcare network.

Growth Advantage

Brazil's modeled 6.15% CAGR is below Mexico's approximately 7.5% but above Colombia's recent 5.8% benchmark, positioning Brazil as a scale leader with mid-to-upper-tier regional growth.

Competitive Strengths

Brazil combines more than 1,618 industrial medical-technology companies, a national SUS network above 101,000 establishments and a policy objective of 70% domestic health-production autonomy by 2033.

CHAPTER 8 - INDUSTRY ANALYSIS

Growth Drivers, Challenges & Opportunities

Comprehensive analysis of key factors shaping the Brazil Medical Device Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments.

Growth Drivers

Healthcare Network Expansion and Procedure Intensity

  • SUS added 3,541 establishments (2025, Brazil), widening the addressable installed base for monitoring, diagnostic, sterilization and treatment equipment. Manufacturers with decentralized technical service capabilities can capture replacement and expansion orders beyond major capitals.
  • Surgical admissions reached approximately 6.48 million (2025, Brazil) and increased 3.6%, supporting recurring utilization of implants, catheters, surgical instruments and disposable supplies. Procedure-linked suppliers benefit directly from throughput rather than solely hospital capital expenditure.
  • SUS recorded approximately 14.4 million hospitalizations (2025, Brazil), expanding the clinical events requiring monitoring, diagnostic testing and therapeutic equipment. Suppliers capable of bundling products with service contracts can convert infrastructure growth into recurring revenue.

Population Aging and Insured Healthcare Demand

  • The 60+ population expanded by 53.3% between 2012 and 2024 (Brazil), increasing demand for cardiology, orthopedics, diabetes management, imaging and home-monitoring devices. Suppliers exposed to chronic disease pathways gain a structurally expanding user base.
  • Private medical plans covered 52.2 million beneficiaries (February 2025, Brazil), creating a large parallel demand pool with stronger access to premium diagnostic and interventional technologies. Hospital groups can justify higher equipment intensity where reimbursement and utilization support lifecycle economics.
  • Brazilian life expectancy reached 76.6 years (2024, Brazil), extending lifetime exposure to chronic and degenerative conditions. This supports multi-year demand for monitoring, implants and diagnostic equipment, especially among providers positioned for repeat care pathways.

Diagnostics, Traceability and Digital Medical Technology

  • ANVISA reported adoption of UDI labeling for Class IV devices from July 2025 (Brazil), increasing traceability requirements and favoring manufacturers with mature serialization, regulatory-data and post-market surveillance systems.
  • The national UDI framework provides up to 6-year phased implementation periods (Brazil) depending on device class, creating a multi-year compliance and data-management agenda for manufacturers, importers and authorization holders.
  • ANVISA has incorporated 79.3% of IMDRF documents (2026, Brazil) according to the sector technology map, supporting gradual convergence with international regulatory practices and potentially improving launch economics for globally documented technologies.

Market Challenges

High Import Exposure and Trade Deficit

  • Exports totaled only approximately USD 1.0 billion (2025, Brazil), leaving a trade deficit near USD 9.2 billion. Importers therefore carry substantial currency, freight and inventory exposure, while policymakers have a clear incentive to encourage localization.
  • Domestic manufacturing grew only 2.6% (2025, Brazil), materially below apparent-consumption growth, indicating that local supply did not fully capture incremental demand. Domestic manufacturers need technology transfer, scale and component ecosystems to close the gap.
  • The United States accounted for approximately 17.1% of medical-device imports (2025, Brazil), with Germany and China also major sources. Concentrated sourcing from external technology centers exposes distributors and hospitals to international logistics and exchange-rate movements.

Regulatory Complexity and Quality Compliance

  • Risk Classes III and IV require valid GMP certification (Brazil) for relevant manufacturing facilities before final authorization, adding quality-system dependencies to commercial launch schedules. Regulatory readiness therefore affects working capital and time to revenue.
  • Selected electromedical products must meet conformity requirements under RDC 549/2021 and IN 283/2024 (Brazil). Certification costs and model-specific technical dossiers can reduce the economics of low-volume product launches.
  • Higher-risk registrations under RDC 751/2022 may remain valid for 10 years (Brazil), but obtaining and maintaining authorization requires local regulatory accountability and post-market controls. Smaller foreign suppliers may therefore depend heavily on experienced Brazilian partners.

Procurement, Tariff and Policy Transition

  • The United States absorbed approximately 25.5% of Brazilian medical-device exports (2025, Brazil), meaning bilateral trade changes can affect domestic manufacturers as well as importers. Export-oriented producers need customer diversification and currency-risk planning.
  • Argentina represented approximately 8.1% of Brazilian sector exports (2025, Brazil), highlighting the importance of neighboring markets but also the concentration of regional export demand. Producers need broader Latin American registration coverage to diversify revenue.
  • Brazil's new tax architecture transitions over 2026-2033 (Brazil), forcing manufacturers and distributors to reassess pricing, credits, contracting and distribution economics while the industry simultaneously manages regulatory and localization requirements.

Market Opportunities

Localization and Import Substitution

  • 70% domestic production target by 2033 (Brazil) creates a monetizable localization thesis around public procurement, contract manufacturing and technology transfer, especially in strategic devices where national supply capability remains limited.
  • Brazil already hosts more than 1,618 industrial medical-technology companies (sector mapping), giving investors and global OEMs a potential supplier, distribution and manufacturing partner base rather than requiring a greenfield ecosystem.
  • National production represented approximately 45% of health-system needs in a 2024 policy benchmark (Brazil), implying that achieving the 2033 objective requires additional capacity, technology transfer and procurement alignment.

Advanced Diagnostics and Connected Devices

  • Software as a Medical Device is specifically addressed by RDC 657/2022 (Brazil), providing a regulatory pathway for digital diagnostic and clinical software vendors. Revenue opportunities extend beyond hardware toward subscriptions, upgrades and analytics.
  • The UDI framework reached mandatory labeling for Class IV devices in July 2025 (Brazil), creating opportunities for serialization, device-data management, hospital inventory integration and post-market surveillance solutions.
  • The SIUD database moved into an operational framework under IN 426 in March 2026 (Brazil), supporting machine-readable device identification and creating infrastructure for more integrated procurement, traceability and lifecycle management.

Ambulatory, Homecare and Private-Sector Expansion

  • The 60+ population reached 34.1 million (2024, Brazil), supporting home monitoring, mobility aids, chronic-care diagnostics and lower-acuity devices that shift selected care outside hospitals.
  • Non-SUS healthcare facilities added more than 20,000 establishments during 2025 (Brazil), expanding the addressable private provider base for equipment, diagnostics and recurring consumables. Vendors with financing and service bundles can target smaller providers.
  • SUS homecare establishments increased rapidly in recent sector monitoring, including a 20.8% increase through September 2025 (Brazil). Portable and connected devices can capture value as care pathways progressively extend into lower-cost non-hospital settings.

CHAPTER 9 - Competitive Landscape

Competitive Landscape Overview

The Brazil Medical Device Market combines global medtech leaders with a large domestic manufacturing and distribution tail. Competition centers on product innovation, regulatory execution, tender access, installed-base service and distributor reach.

Market Share Distribution

Philips
GE HealthCare
Siemens Healthineers
Abbott

Top 5 Players

1
Philips
!$*
2
GE HealthCare
^&
3
Siemens Healthineers
#@
4
Abbott
$
5
Medtronic
&@$
Combined Share$%

Market Dynamics

Local Players70%
Regional/Int'l30%

8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.

Company Profiles (Top 10 Players)
Company Name
Market Share
Headquarters
Founding Year
Core Market Focus
Philips
-Amsterdam, Netherlands1891Diagnostic imaging, ultrasound, patient monitoring and connected care
GE HealthCare
-Chicago, United States2023Imaging, ultrasound, patient monitoring and clinical systems
Siemens Healthineers
-Erlangen, Germany2017Imaging, laboratory diagnostics and image-guided therapy
Abbott
-Abbott Park, Illinois, United States1888Diagnostics, diabetes care and cardiovascular devices
Medtronic
-Galway, Ireland1949Cardiovascular, surgical, diabetes and neurological devices
Johnson & Johnson MedTech
-New Brunswick, New Jersey, United States1886Surgery, orthopedics and cardiovascular intervention
Becton, Dickinson and Company
-Franklin Lakes, New Jersey, United States1897Medication delivery, diagnostics and bioscience devices
Baxter
-Deerfield, Illinois, United States1931Infusion systems, hospital products and critical-care technologies
B. Braun
-Melsungen, Germany1839Infusion, surgical, renal and hospital-care devices
Boston Scientific
-Marlborough, Massachusetts, United States1979Interventional cardiology, endoscopy, urology and peripheral intervention

Cross Comparison Parameters

The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.

1

Installed Base and Service Coverage

2

Regulatory Approval and Launch Velocity

3

Brazil Medical Device Revenue Growth

4

Gross Margin

Analysis Covered

Market Share Analysis:

Benchmarks competitive scale across multinational and domestic medical-device suppliers nationally

Cross Comparison Matrix:

Compares operating reach, approvals, revenue momentum and profitability performance indicators

SWOT Analysis:

Assesses technology strengths, portfolio gaps, localization exposure and strategic threats

Pricing Strategy Analysis:

Evaluates premium positioning, tender pricing, distributor margins and lifecycle economics

Company Profiles:

Reviews portfolio focus, geographic presence, strategic priorities and operating capabilities

CHAPTER 10 - REPORT TOC

Table of Contents

94Pages
34Chapters
10Companies Profiled
7Segmentation Types

Phase 1
Market Assessment Phase

11

Chapters

Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.

Phase 2
Go-To-Market Strategy Phase

15

Chapters

Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.

Complete Report Coverage

201+ detailed sections covering every aspect of the market

143

Assessment Sections

58

Strategy Sections

CHAPTER 11 - Our Approach

Research Methodology

Desk Research

  • ANVISA device regulations and classifications
  • SUS facility and procedure statistics
  • Medical-device import export flow analysis
  • Manufacturer filings and portfolio mapping

Primary Research

  • Brazil medtech country manager interviews
  • Hospital procurement director consultations conducted
  • Biomedical engineering manager interviews conducted
  • Distributor commercial director discussions conducted

Validation and Triangulation

  • 346 respondent inputs cross-validated
  • Supply demand estimates independently reconciled
  • Trade flows checked against consumption
  • Forecast assumptions scenario tested annually

CHAPTER 12 - FAQ

FAQs

Still have questions?

Our research team is here to help you find the right solution

Contact Research Team

CHAPTER 13 - Related Research

Explore Related Reports

Expand your market intelligence with complementary research across regions and adjacent markets.

500+

Market Research Reports

50+

Countries Covered

15+

Industry Verticals

Want the full report and an analyst walkthrough?

Unlock the complete dataset, segmentation cuts, and competitive analysis—plus a discovery call that maps insights to your go-to-market priorities.

;